XNASNTRB
Market cap47mUSD
Jan 08, Last price
4.27USD
1D
-4.04%
1Q
-39.86%
IPO
-35.30%
Name
Nutriband Inc
Chart & Performance
P/E
—
P/S
22.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.96%
Rev. gr., 5y
53.43%
Revenues
2m
+0.27%
Net income
-5m
L+14.02%
CFO
-4m
L+18.09%
Earnings
May 29, 2025
Profile
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | 2020‑01 | 2019‑01 | 2018‑01 | 2017‑01 | 2016‑01 | |
| Income | |||||||||
Revenues | 2,085 0.27% | 2,080 46.23% | 1,422 50.70% | ||||||
Cost of revenue | 3,184 | 2,311 | 5,352 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,098) | (232) | (3,930) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 327 | 2,246 | |||||||
Tax Rate | |||||||||
NOPAT | (1,098) | (559) | (6,176) | ||||||
Net income | (5,485) 14.02% | (4,811) -42.88% | (8,422) 162.09% | ||||||
Dividends | (197) | ||||||||
Dividend yield | 0.57% | ||||||||
Proceeds from repurchase of equity | 2,608 | 178 | 6,315 | ||||||
BB yield | -12.56% | -0.58% | -18.22% | ||||||
| Debt | |||||||||
Debt current | 196 | 51 | 33 | ||||||
Long-term debt | 114 | 200 | 120 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | (101) | ||||||||
Net debt | (183) | (1,734) | (4,738) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (3,528) | (2,987) | (2,809) | ||||||
CAPEX | (52) | (79) | (82) | ||||||
Cash from investing activities | (52) | (79) | (82) | ||||||
Cash from financing activities | 2,087 | 160 | 7,631 | ||||||
FCF | (933) | (532) | (6,811) | ||||||
| Balance | |||||||||
Cash | 493 | 1,985 | 4,892 | ||||||
Long term investments | |||||||||
Excess cash | 389 | 1,881 | 4,821 | ||||||
Stockholders' equity | (27,971) | (22,487) | (18,004) | ||||||
Invested Capital | 34,911 | 31,246 | 29,998 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 7,954 | 8,460 | 7,933 | ||||||
Price | 2.61 -28.49% | 3.65 -16.48% | 4.37 -75.72% | ||||||
Market cap | 20,760 -32.77% | 30,877 -10.93% | 34,667 -71.39% | ||||||
EV | 20,577 | 29,143 | 29,929 | ||||||
EBITDA | (811) | 137 | (3,612) | ||||||
EV/EBITDA | 212.51 | ||||||||
Interest | 76 | 8 | 118 | ||||||
Interest/NOPBT | |||||||||